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Disclaimer
The content of all Presentations, such as for example but not limited to information, statements, opinions or matters, representations, data, etc. 
contained and/or indicated – regardless of whether expressed or implied - may be incomplete, incorrect, is subject to change, completion, 
amendment, etc., bases on estimates only, may include omissions, involves significant elements of subjective judgment and analysis which may or 
may not be accurate (“Content”).
Therefore, the recipient must not rely or lean on any Content. This also applies for anything arising out of and/or deriving from Content and/or from 
any omission from Content, such as for example but not limited to projections, forecasts, assumptions, conclusions, the achievement or 
reasonableness of any plans, future projections, management targets, prospects or returns, etc. (“Derivations”) No recipient must expect Glycotope 
to owe it any duties or responsibilities with respect to any potential or future transaction, joint venture, purchase of any shares or license in or the 
business of Glycotope, investment, etc. (“Transaction”). For the sake of clarity, the documents do not constitute any claim to enter a Transaction.  
To the maximum extent permitted by law, Glycotope does not represent and/or take any responsibility, liability, representation or warranty, etc. 
(including without limitation for negligence)   for any Content and Derivations as well as for any omission from Content and Derivations and expressly 
disclaims from any and all responsibility, liability, representations and warranty, etc. (including without limitation for negligence) arising from Content, 
Derivations and this Presentation and any omissions therefrom.  This also applies for any other written or oral communications transmitted or made 
available including, without limitation, any information, any estimates or projections and any other information derived therefrom.  The provision of 
this Presentation is not and should not be considered as a recommendation in relation to a Transaction or shall in no case obligate Glycotope to 
agree to any duties or responsibilities in connection with any transaction. Any claims regarding damages, etc. caused by the use of Content, 
Deviations and Presentation and any omission therefrom will therefore be rejected.
This disclaimer is to be regarded as a part of the Presentations. If sections or individual terms of this statement are not legal or correct, the content 
or validity of the other parts remain uninfluenced by this fact.
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Biopharmaceutical expertise at Glycotope
2Poster Presentations - Continuous Culture to Capture - Poster 17
Glycosylation Source: http://www.nyhf.org/wp-content/uploads/2017/05/glycoprotein.jpg Source: http://www.airwaytherapeutics.com/at-100/
Experts in perfusion production of biopharmaceuticals
Proprietary human GEX™ cell line
 well suited for glyco-optimized and hard-to-express proteins
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SAM-perfusion, Up-Scaling and Down-Scaling
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Downscale feasible using SAM-Perfusion 
in AMBR15
Up-Scale feasible to 1000L SUB
Glycosylation profile
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